Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Oncology|June 5, 2010
Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research GroupSofia Agelaki, Dora Hatzidaki, Athanasios Kotsakis, et al.
NPJ Precision Oncology|December 26, 2024
Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancerKaterina Tsilingiri, Anna Chalari, Georgia Christopoulou, et al.
Targeted Oncology|June 17, 2019
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal CancerAlexios Matikas, John Souglakos, Panagiotis Katsaounis, et al.
Cancer Immunology, Immunotherapy : CII|October 9, 2025
Profiling of circulating T-cells with prognostic and predictive value in early and advanced stage PDACAnastasia Xagara, Konstantina Vasilieva, Alexandros Kokkalis, et al.
Annals of Gastroenterology|January 16, 2018
Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research GroupPanagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, et al.
Head & Neck|May 28, 2016
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinomaJessica L Geiger, Julie E Bauman, Michael K Gibson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 13, 2011
Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patientsEleni-Kyriaki Vetsika, Elisavet Papadimitraki, Despoina Aggouraki, et al.
BMC Cancer|June 1, 2007
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II studyChristos Emmanouilides, Georgia Sfakiotaki, Nikolaos Androulakis, et al.
Lung Cancer (Amsterdam, Netherlands)|September 4, 2007
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trialVassilis Georgoulias, Nikolaos Androulakis, Athanasios Kotsakis, et al.
Cancers|September 28, 2023
Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker StudyFilippos Koinis, Zafeiris Zafeiriou, Ippokratis Messaritakis, et al.
Pageof 13